[{"id":"aa8a7e52-6359-433f-a744-82dc9c3ad3fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT02933255","created_at":"2021-01-18T14:24:28.924Z","updated_at":"2024-07-02T16:34:59.701Z","phase":"Phase 1/2","brief_title":"PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer","source_id_and_acronym":"NCT02933255","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • ProstVac (rilimogene galvacirepvec)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 04/18/2017","start_date":" 04/18/2017","primary_txt":" Primary completion: 06/20/2023","primary_completion_date":" 06/20/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2024-05-31"},{"id":"590e53d1-c310-49ee-97e0-d23db9389e60","acronym":"16-C-0048","url":"https://clinicaltrials.gov/study/NCT02649855","created_at":"2023-07-21T15:09:43.248Z","updated_at":"2024-07-02T16:35:31.054Z","phase":"Phase 2","brief_title":"Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer","source_id_and_acronym":"NCT02649855 - 16-C-0048","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • IFNG • MUC1 • TNFA • CEACAM5 • CD4 • IL2 • LAMP1","pipe":"","alterations":" ","tags":["CD8 • IFNG • MUC1 • TNFA • CEACAM5 • CD4 • IL2 • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • ProstVac (rilimogene galvacirepvec)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 01/19/2016","start_date":" 01/19/2016","primary_txt":" Primary completion: 07/01/2022","primary_completion_date":" 07/01/2022","study_txt":" Completion: 08/08/2024","study_completion_date":" 08/08/2024","last_update_posted":"2023-10-31"},{"id":"6995371f-14d0-437d-91fa-8e1b8845e670","acronym":"","url":"https://clinicaltrials.gov/study/NCT02326805","created_at":"2021-01-18T11:02:21.838Z","updated_at":"2024-07-02T16:35:42.583Z","phase":"Phase 2","brief_title":"PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance","source_id_and_acronym":"NCT02326805","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD8 • CD4","pipe":" | ","alterations":" PD-L1 expression • CD4 positive","tags":["PD-L1 • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • CD4 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ProstVac (rilimogene galvacirepvec)"],"overall_status":"Completed","enrollment":" Enrollment 154","initiation":"Initiation: 06/03/2015","start_date":" 06/03/2015","primary_txt":" Primary completion: 11/30/2018","primary_completion_date":" 11/30/2018","study_txt":" Completion: 07/20/2022","study_completion_date":" 07/20/2022","last_update_posted":"2023-07-19"},{"id":"21a6ee89-cf41-4d26-aa77-6f7cce68dde5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02153918","created_at":"2021-01-18T10:01:01.104Z","updated_at":"2024-07-02T16:37:06.141Z","phase":"Phase 2","brief_title":"Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy","source_id_and_acronym":"NCT02153918","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • CD4 • FOXP3","pipe":"","alterations":" ","tags":["CD8 • CD4 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ProstVac (rilimogene galvacirepvec)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 05/31/2014","start_date":" 05/31/2014","primary_txt":" Primary completion: 07/28/2017","primary_completion_date":" 07/28/2017","study_txt":" Completion: 01/16/2018","study_completion_date":" 01/16/2018","last_update_posted":"2018-10-12"}]